NNBXF Nanobiotix S.A.

Price Chart

Executive Summary

Nanobiotix closed its global offering of 2,218,467 ordinary shares (including ADSs) and 345,099 pre-funded warrants, raising approximately $100 million in gross proceeds. The offering was fully upsized via underwriter option exercise, and the company expects the net proceeds, combined with existing cash, to fund operations into 2029. This filing confirms the capital raise previously announced in the preliminary prospectus, removing overhang uncertainty but introducing ~4.5% dilution to existing shareholders.

Actionable Insight

Key Facts

• Closed global offering of 2,218,467 ordinary shares and 345,099 pre-funded warrants
• Gross proceeds of approximately $100 million (€86.1 million)
• Underwriters fully exercised their option to purchase additional ADSs (33,805 shares)
• Subscription price of €33.60 per share ($38.98 per ADS), a 14.92% discount to VWAP
• Net proceeds allocated: <10% to JNJ-1900 (NBTXR3), 50-60% to Nanoprimer/other platforms, 30-40% for general corporate purposes
• Company believes cash runway extends into 2029
• Offering was made under an effective shelf registration statement (F-3, No. 333-285604)

Financial Impact

Gross proceeds of ~$100 million; net proceeds after underwriting commissions and expenses will fund operations into 2029

Risk Factors

• Dilution of ~4.5% to existing shareholders from the offering
• Execution risk on pipeline programs (JNJ-1900, Nanoprimer) despite extended cash runway
• Potential for further capital needs if clinical timelines slip or costs exceed projections

Market Snapshot

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

US Market Status

Related Tickers